Eric F. Morand

Trial of Anifrolumab in Active Systemic Lupus Erythematosus

Eric F. Morand, Richard Furie, Yoshiya Tanaka et al. · New England Journal of Medicine · 2019 · 1.3K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +9

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Antonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen et al. · Annals of the Rheumatic Diseases · 2023 · 933 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)

Kate Franklyn, Chak Sing Lau, Sandra Navarra et al. · Annals of the Rheumatic Diseases · 2015 · 735 citations

Medicine, Clinical Sciences, Internal Medicine +17

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

Jing He, Xia Zhang, Yunbo Wei et al. · Nature Medicine · 2016 · 572 citations

Life Sciences, Immunology, Autoimmunity +15

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Richard Furie, Eric F. Morand, Ian N Bruce et al. · The Lancet Rheumatology · 2019 · 482 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14